New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened by...
Read More
New data from insurers show detriments of copay accumulator adjustment programs

Commercial health insurers are starting to admit what the biopharmaceutical research industry has been warning for some time: copay accumulator adjustment programs hurt patient outcomes and shift...
Read More
Patient safety is at the heart of COVID-19 vaccine R&D

As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is continuing working around the clock to research, develop and manufacture vaccines to prevent...
Read More
Data shows that Americans are relying on vaccines to get us through the pandemic

As we continue to combat the pandemic, America’s biopharmaceutical industry is working around the clock in unprecedented partnerships to manufacture COVID-19 vaccines, reaching billions of doses by...
Read More
West Virginia becomes the first state to lower patient costs by sharing the savings

In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and their PBMs to share...
Read More
What they are saying: Experts highlight the importance of IP in recent NIST proposal comments

Strong, reliable, and clearly defined intellectual property (IP) protections are the foundation of America’s robust innovation ecosystem that patients across the globe rely on for the research and...
Read More
PhRMA member companies share how they are improving clinical trial diversity

As part of the biopharmaceutical industry’s efforts to improve health outcomes for patients in underserved communities, PhRMA member companies are identifying ways to improve clinical trial diversity...
Read More
Our three-part approach to build a better health care system

On April 3, more than four million Americans received a COVID-19 vaccine — the largest single-day vaccination event in human history. For innovators across the pharmaceutical industry, these moments...
Read More
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures

America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing...
Read More
Diversifying clinical trials and fighting disease requires equity and trust

The COVID-19 pandemic has left no person unaffected, but Black Americans have been disproportionately impacted. Black adults are nearly four times more likely to be hospitalized from the virus and...
Read More
Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections

Earlier this week PhRMA submitted comments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed in...
Read More